Paclitaxel poliglumex promising in heavily-pretreated ovarian cancer

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1467, 2004-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel poliglumex for ovarian cancer

By Galic Vijaya L Wright Jason D Lewin Sharyn N Herzog Thomas J

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 813-821

Informa Healthcare

Access to resources Recommend Favorite

Chronic Administration of Single Weekly Paclitaxel in Heavily Pretreated Ovarian Cancer Patients

Current Medicinal Chemistry, Vol. 11, Iss. 4, 2004-02 ,pp. : 425-428

Bentham Science Publishers

Access to resources Recommend Favorite

PHARMACOLOGIC STUDY OF 3-HOUR 135 mg m^-² PACLITAXEL IN PLATINUM PRETREATED PATIENTS WITH ADVANCED OVARIAN CANCER

By Panday V.R.N.A.N.N.A.N. Huizing M.T. van WARMERDAM L.J.C. Dubbelman R.C. Mandjes I. Schellens J.H.M. Huinink W.W.T.E.N.B.O.K.K.E.L. Beijnen J.H.

Pharmacological Research, Vol. 38, Iss. 3, 1998-01 ,pp. : 231-236

Academic Press

Access to resources Recommend Favorite

Paclitaxel poliglumex a stellar performer in NSCLC

Inpharma, Vol. 1, Iss. 1517, 2005-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Paclitaxel vs cyclophosphamide, + cisplatin, for ovarian cancer

Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite